Allogeneic hematopoietic stem cell donation - Standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 220-225

  Halter, J P ^a   Van Walraven, S M ^b   Worel, N ^c   Bengtsson, M ^d   Hagglund H ^d   Nicoloso De Faveri, G ^e   Shaw, B E ^f,g   Schmidt, A H ^h   Fechter, M ⁱ   Madrigal, A ^j   Szer, J ^k   Aljurf, M D ^l   Weisdorf, D ^m   Horowitz, M M ⁿ   Greinix, H ^c   Niederwieser, D ^o   Gratwohl, A ^a   Kodera, Y ^o,p   Confer, D ^q  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e Foundation Swiss Blood Stem Cells   (Switzerland)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h DKMS German Bone Marrow Donor Center   (Germany)

ⁱ Europdonor Foundation Leiden   (Netherlands)

^j ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

^l KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^m UNIVERSITY OF MINNESOTA   (United States)

ⁿ CIBMTR   (United States)

^o UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^p AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q NATIONAL MARROW DONOR PROGRAM   (United States)

more..

Author keywords

donor outcome; global donor follow up; minimal data set; serious adverse reactions; WBMT

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CONSENSUS; DONOR SELECTION; HEMATOLOGIC MALIGNANCY; HUMAN; INTERNET; LIVING DONOR; PATIENT COUNSELING; PATIENT SAFETY; PRIORITY JOURNAL; TREATMENT OUTCOME; UNRELATED DONORS;

ADOLESCENT; ADULT; DONOR SELECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84873482650     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.119     Document Type: Article

References (48)

1. Pasquini M.C. Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides 2010 Available at http://www.cibmtr. org
2. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: A global perspective. JAMA 2010; 303: 1617-1624
3. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A et al. The EBMT activity survey 2009: Trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485-501
4. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC et al. Marrow harvesting from normal donors. Blood 1984; 64: 630-634
5. Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: Considerations for donors. Blood 1997; 90: 903-908
6. Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S et al. Clinical Working Group; Ethics Working Group of the WMDA. Donor safety: The role of the WMDA in ensuring the safety of volunteer unrelated donors: Clinical and ethical considerations. Bone Marrow Transplant 2010; 45: 832-838
7. van Walraven SM, Nicoloso-de Faveri G, Axdorph-Nygell UA, Douglas KW, Jones DA, Lee SJ et al. WMDA ethics and clinical working groups. Family donor care management: Principles and recommendations. Bone Marrow Transplant 2010; 45: 1269-1273
8. World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation 2010; 90: 229-233
9. Miller JP, Perry EH, Price TH, Bolan Jr CD, Karanes C, Boyd TM et al. Recovery and safety profiles of marrow and PBSC donors: Experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14(9 Suppl): 29-36
10. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: Results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604-3611
11. Hölig K, Kramer M, Kroschinsky F, Bornha?user M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757-3763
12. Favre G, Beksaç M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. European Group for Blood and Marrow Transplantation (EBMT). Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873-880
13. Bredeson C, Leger C, Couban S, Simpson D, Huebsch L, Walker I et al. An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 2004; 10: 405-414
14. Tassi C, Tazzari PL, Bonifazi F, Giudice V, Nannetti A, Ricci F et al. Short- and longterm haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: A single institution prospective study. Bone Marrow Transplant 2005; 36: 289-294
15. de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Followup of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735-740
16. Horowitz MM, Confer DL. Evaluation of hematopoietic stem cell donors. Hematology Am Soc Hematol Educ Program 2005; 469-475
17. Confer DL, Miller JP, Chell JW. Bone Marrow and peripheral blood cell donors an donor registries. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds) Thomas' Hematopoietic Cell Transplantation. 4th edn. Blackwell Publishing, John Wiley & Sons Ltd, Chichester, West Sussex, UK, 2009, pp 544-558
18. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94-101
19. Kodera Y, Yamamoto K, Kato S, Harada M, Kanda Y, Hamajima N et al. Safety and Risk of Allogeneic Peripheral Blood Stem Cell Donation: The Comprehensive Report of Nation-Wide Consecutively Pre-Registered 3,264 Family Donor Survey in 10years Project by Japan Society for Hematopoietic Cell Transplantation, ASH 2010; Poster 1180
20. Niederwieser D, Gentilini C, Hegenbart U, Lange T, Moosmann P, Pönisch W et al. Transmission of donor illness by stem cell transplantation: Should screening be different in older donors? Bone Marrow Transplant 2004; 34: 657-665
21. Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al. Quality Assurance and Clinical Working Groups of the World Marrow Donor Association. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008; 42: 9-14
22. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: Report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642-650
23. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651-652
24. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77-78
25. Bacher U, Zander AR. Long-term safety of filgrastim (rhG-CSF) administration: Application of haematopoietic growth factors in healthy individuals. Br J Haematol 2007; 137: 78-79
26. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colonystimulating factor in healthy individuals: Recent findings and current challenges. Blood 2008; 111: 1767-1772
27. Tagliari C, Florêncio R, Ostronoff M. Fatal complication of peripheral blood stem cell (PBSC) donor after granulocyte-colony stimulating factor (G-CSF) stimulation. ISH 2010; Poster 192
28. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte- colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008; 48: 1495-1501
29. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhGCSF. Bone Marrow Transplant 2003; 32: 31-34
30. Herna'ndez JM, Castilla C, Gutié rrez NC, Isidro IM, Delgado M, de las Rivas J et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19: 1088-1091
31. Hirsch B, Oseth L, Cain M, Trader E, Pulkrabek S, Lindgren B et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118: 2602-2608
32. Schmidt AH, Mengling T, Pingel J, Rall G, Ehninger G. Follow up of 12559 unrelated donors of peripheral blood stem cells or bone marrow. ASH 2010
33. Hasenclever D, Sextro M. Safety of AlloPBPCT donors: Biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17(Suppl 2): S28-S30
34. Jin P, Wang E, Ren J, Childs R, Shin JW, Khuu H et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med 2008; 6: 39
35. Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34 cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008; 93: 347-355
36. Donahue RE, Jin P, Bonifacino AC, Metzger ME, Ren J, Wang E et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34 cell populations based on global gene and microRNA expression signatures. Blood 2009; 114: 2530-2541
37. Bortin MM, D'Amaro J, Bach FH, Rimm AA, van Rood JJ. HLA associations with leukemia. Blood 1987; 70: 227-232
38. Wang SS, Slager SL, Brennan P, Holly EA, De Sanjose S, Bernstein L et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): A pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109: 3479-3488
39. Kroschinsky F, Hundertmark J, Mauersberger S, Hermes M, Poppe-Thiede K, Rutt C et al. Severe autoimmune hyperthyroidism after donation of growth factorprimed allogeneic peripheral blood progenitor cells. Haematologica 2004; 89: ECR05
40. Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T et al. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: A single centre experience. Bone Marrow Transplant 2009; 44: 163-168
41. Nicolini FE, Wattel E, Michallet AS, Bourgeot JP, Tremisi JP, Hequet O et al. Longterm persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion. Exp Hematol 2004; 32: 1033-1039
42. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214 http://www.worldmarrow.org/see adverse events
43. Leitner GC, Baumgartner K, Kalhs P, Biener D, Greinix HT, Hoecker P et al. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: A cross-sectional study. Bone Marrow Transplant 2009; 43: 357-363
44. Machaczka M, Kalaitzakis E, Eleborg L, Ljungman P, Ha?gglund H. Comparison of general vs regional anaesthesia for BM harvesting: A retrospective study of anaesthesia-related complications. Bone Marrow Transplant 2010; 45: 53-61
45. Jeger A, Favre G, Lutz JM, Stern M, Usel M, Rovo A et al. Tumor incidence in related hematopoietic stem cell donors. Bone Marrow Transplant 2011; 46: 1240-1244
46. Al-Ali HK, Bourgeois M, Krahl R, Edel E, Leiblein S, Poenisch W et al. The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46: 1296-1302
47. Confer DL, Shaw BE, Pamphilon DH. WMDA guidelines for subsequent donations following initial BM or PBSCs. Bone Marrow Transplant 2011; 46: 1409-1412
48. O'Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher MA, Stroncek D et al. Donor Health and Safety Working Committee from Center for International Blood and Marrow Transplant Research (CIBMTR). Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood 2010; 115: 5097-5101